Skip to main content

Table 1 Results of biochemical tests to evaluate renal and hepatic toxicity of sorafenib and CKD-5 treatment

From: CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

 

Control

Sorafenib

CKD-5

CKD-5 + sorafenib

Creatinine (mg/dL)

0.43 ± 0.03

0.41 ± 0.04

0.39 ± 0.02

0.37 ± 0.04*

ALT (mg/dL)

221.50 ± 188.65

78.44 ± 45.41*

67.75 ± 41.98*

70.00 ± 30.71*

AST (mg/dL)

578.25 ± 166.24

452.7 ± 77.16

378.88 ± 154.01*

412.38 ± 91.83

Weight (g)

25.62 ± 0.94

24.97 ± 0.97

24.76 ± 1.27

24.67 ± 1.17

  1. ALT Alanine transaminase, AST Aspartate transaminase
  2. * P < 0.05 compared to control
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us